- Preclinical results demonstrate effectiveness of vaccine even at
extremely low doses -
QUEBEC CITY, Nov. 20 /CNW/ - Medicago Inc. (TSX-V: MDG) today announced
additional positive results from a preclinical study of its H5N1 Influenza
Virus-Like Particles ("VLP") vaccine. Medicago previously reported that its
proprietary VLP vaccine stimulates a significant seroprotective immune
response against the lethal Indonesia strain of the H5N1 Avian Influenza virus
in mice who received doses as low as 1 microgram (ug). The Company has now
generated additional data showing that a strong protective immune response is
achieved against this virus at even lower doses of only 0.1 ug.
"These unprecedented data position Medicago at the forefront of influenza
vaccine development," said Andy Sheldon, President and CEO. "A typical dose
for a pandemic flu vaccine is 15-30 ug. If we are able to reproduce these
results in human clinical trials, our technology has the potential to
significantly increase the world's currently limited vaccine manufacturing
capacity, allowing for the protection of a greater number of people in the
event of a pandemic influenza outbreak."
"This 0.1ug dose is amongst the lowest doses ever recorded," said Dr.
Louis Vezina, Medicago's Chief Scientific Officer. "At this very low dose,
Medicago's VLP vaccine generated neutralizing antibody levels in mice three
times higher than the minimal level required to obtain protection against an
influenza infection. Based on these results, we will continue studies to
determine the lowest effective dose"
About Medicago Inc.
Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in the cells of non-transgenic plants. This technology has
potential to offer advantages of speed and cost over competitive technologies.
It could deliver a vaccine for testing in about a month after the
identification and reception of genetic sequences from a pandemic strain. This
production time frame has the potential to allow vaccination of the population
before the first wave of a pandemic strikes and to supply large volumes of
vaccine antigens to the world market.
Additional information about Medicago is available at www.medicago.com.
Forward Looking Statements
This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.
The TSX Venture Exchange assumes no responsibility for the content or
accuracy of this press release.
For further information:
For further information: Contact Information: Medicago Inc., Andy
Sheldon, President and CEO, (418) 658-9393; The Equicom Group Inc., Eric
Bouchard, Investor Relations, (514) 844-7997, email@example.com